Back to top
more

Incyte (INCY)

(Delayed Data from NSDQ)

$76.13 USD

76.13
2,260,926

+2.01 (2.71%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $75.81 -0.32 (-0.42%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Smart Beta ETF report for XBI

INCY Q3 Earnings Miss Estimates, Revenues Beat on Higher Product Sales

Incyte reports mixed third-quarter results as earnings miss estimates while revenues beat the same due to increased sales of Jakafi and Opzelura.

Here's What Key Metrics Tell Us About Incyte (INCY) Q3 Earnings

The headline numbers for Incyte (INCY) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Incyte (INCY) Q3 Earnings Miss Estimates

Incyte (INCY) delivered earnings and revenue surprises of -4.46% and 4.47%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Incyte Gears Up to Report Q3 Earnings: Here's What You Should Know

INCY's third-quarter 2024 earnings are likely to have gained from higher Jakafi and Opzelura sales.

GMAB or INCY: Which Is the Better Value Stock Right Now?

GMAB vs. INCY: Which Stock Is the Better Value Option?

Incyte Gains 12.7% Year to Date: How Should You Play the Stock?

Though INCY's performance in the year so far has been good, increasing competition for Jakafi is a concern. We advise investors to wait and watch before turning positive.

Is Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) a Strong ETF Right Now?

Smart Beta ETF report for JSMD

Incyte Announces Promising New Data on Oncology Candidate at ESMO

INCY's INCB123667 data show the candidate's potential as a differentiated treatment option for cancers with increased cyclin E1 activity, amplification and/or overexpression in cells predictive of CDK2 dependency.

Allogene Therapeutics (ALLO) Up 6.4% Since Last Earnings Report: Can It Continue?

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Glaxo (GSK) Up 10.3% Since Last Earnings Report?

Glaxo (GSK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Incyte (INCY) Up 0.9% Since Last Earnings Report: Can It Continue?

Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ekta Bagri headshot

Biotech Stock Roundup: CRL for REGN, GILD's Drug Approval, LQDA Down on News

Bigwigs Regeneron (REGN) and Gilead Sciences (GILD) are in the spotlight following regulatory updates and drug approval, respectively.

Incyte (INCY) Announces Data on Monjuvi, FDA Approval for GVHD Drug

Incyte???s (INCY) late-stage study on tafasitamab for patients with relapsed or refractory follicular lymphoma meets its goal. FDA approves axatilimab for the treatment of chronic graft-versus-host disease.

Do Options Traders Know Something About Incyte (INCY) Stock We Don't?

Investors need to pay close attention to Incyte (INCY) stock based on the movements in the options market lately.

Incyte's (INCY) Q2 Earnings Lag Estimates, Revenues Top

Incyte's (INCY) second-quarter 2024 earnings miss estimates while revenues beat the same. The company raises the bottom end of the 2024 revenue guidance for its lead drug, Jakafi.

Incyte (INCY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Although the revenue and EPS for Incyte (INCY) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Incyte (INCY) Reports Q2 Loss, Tops Revenue Estimates

Incyte (INCY) delivered earnings and revenue surprises of -333.33% and 2.39%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Is a Beat in the Cards for Incyte (INCY) in Q2 Earnings?

On Incyte's (INCY) second-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its lead drug, Jakafi, which has been facing stiff competition.

Qiagen (QGEN) Expected to Beat Earnings Estimates: Should You Buy?

Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth

Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Agilent (A) Boosts DCG Segment With New ProteoAnalyzer System

Agilent (A) unveils its new ProteoAnalyzer system in a bid to strengthen its Diagnostics and Genomics Group segment.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

INCY or MYGN: Which Is the Better Value Stock Right Now?

INCY vs. MYGN: Which Stock Is the Better Value Option?